Goserelin

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

For patient information, click here.

Goserelin
Clinical data
SynonymsD-Ser(But)6Azgly10LHRH
Pregnancy
category
  • D (3.6mg) / X (10.8mg) (USA)
Routes of
administration
implant
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding27.3%
Elimination half-life4-5 hours
Excretionrenal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC59H84N18O14
Molar mass1269.410 g/mol

WikiDoc Resources for Goserelin

Articles

Most recent articles on Goserelin

Most cited articles on Goserelin

Review articles on Goserelin

Articles on Goserelin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Goserelin

Images of Goserelin

Photos of Goserelin

Podcasts & MP3s on Goserelin

Videos on Goserelin

Evidence Based Medicine

Cochrane Collaboration on Goserelin

Bandolier on Goserelin

TRIP on Goserelin

Clinical Trials

Ongoing Trials on Goserelin at Clinical Trials.gov

Trial results on Goserelin

Clinical Trials on Goserelin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Goserelin

NICE Guidance on Goserelin

NHS PRODIGY Guidance

FDA on Goserelin

CDC on Goserelin

Books

Books on Goserelin

News

Goserelin in the news

Be alerted to news on Goserelin

News trends on Goserelin

Commentary

Blogs on Goserelin

Definitions

Definitions of Goserelin

Patient Resources / Community

Patient resources on Goserelin

Discussion groups on Goserelin

Patient Handouts on Goserelin

Directions to Hospitals Treating Goserelin

Risk calculators and risk factors for Goserelin

Healthcare Provider Resources

Symptoms of Goserelin

Causes & Risk Factors for Goserelin

Diagnostic studies for Goserelin

Treatment of Goserelin

Continuing Medical Education (CME)

CME Programs on Goserelin

International

Goserelin en Espanol

Goserelin en Francais

Business

Goserelin in the Marketplace

Patents on Goserelin

Experimental / Informatics

List of terms related to Goserelin

Overview

Goserelin Acetate is an injectable gonadotropin releasing hormone super-agonist (GnRH agonist). It stops the production of sex hormones (testosterone and oestrogen).

Goserelin Acetate is marketed by AstraZeneca with the brand name Zoladex.[1] It was first launched in 1987 and is currently the second-largest selling GnRH analogue in the world. It is currently available in more than one hundred markets.

Zoladex 3.6 mg subcutaneous monthly biodegradable implant was first approved by the FDA on November 3, 1989[2] for treatment of prostate cancer, a 10.8 mg subcutaneous 3-month biodegradable implant and other indications were subsequently approved.

Pharmacokinetics

Goserelin is a synthetic analogue of a naturally occurring luteinising-hormone releasing hormone (LHRH). Bioavailability is almost complete. Gosereline is poorly protein bound and has a serum elimination half-life of two to four hours in patients with normal renal function. The half-life increases with patients with impaired renal function. There is no significant change in pharmacokinetics in subjects with hepatic failure. After administration, peak serum concentrations are reached in about two hours. It rapidly binds to the LHRH receptor cells in the pituitary gland thus leading to an initial increase in production of luteinizing hormone and thus leading to an initial increase in the production of corresponding sex hormones. This initial Flare may be treated by co-prescribing/co-administering Casodex (Bicalutamide) or similar medication. Eventually, after a period of about 14-21 days, production of LH is greatly reduced due to receptor downregulation, and sex hormones are generally reduced to castrate levels.[3]

Indications

Goserelin Acetate is used to treat hormone-sensitive cancers of the prostate and breast (in pre-/perimenopausal women) and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty. The syringe applicator comes with a protective sleeve, called the SafeSystem, to reduce and prevent needlestick injuries to administering healthcare professionals.

It is available as a 1-month depot and a long-acting 3-month depot. Both depots are used for the treatment of prostate cancer, endometriosis and uterine fibroids but only the 1-month depot is approved for breast cancer, endometrial thinning and assisted reproduction.

NOTE: The above license is probably from the USA. It should be noted that licensed indications may vary from country to country. For example, in the UK the 1-month depot is licensed for prostate cancer, endometriosis, uterine fibroids, breast cancer, endometrial thinning and assisted reproduction, and not as above. You are advised to consult a Healthcare Professional or your local regulatory authorities if you need more information on your local license for this product.

Side effects

Goserelin Acetate may cause a temporary increase in bone pain and symptoms of prostatic cancer during the first few weeks of treatment. As the body adjusts to the medication, the symptoms will disappear. Goserelin may cause hot flushes, headache, stomach upset, difficulty urinating (isolated cases), weight gain, swelling and tenderness of breasts (infrequent), decreased erections, reduced sexual desire. Bone pain can be managed symptomatically, and decreased libido can be treated by Levitra (Vardenifil) or other similar oral therapies.

Interactions

No known interaction with other medicinal products.

Effects on ability to drive and operate machinery

There is no evidence that Goserelin Acetate results in impairment of these activities.

References

  1. AstraZeneca official Zoladex site
  2. FDA Approval for Zoladex 3.6 mg
  3. Kotake, Toshihiko (August 1999). "Goserelin Acetate with or without Antiandrogen or Estrogen in the Treatment of Patients with Advanced Prostate Cancer: a Multicenter, Randomized, Controlled Trial in Japan". Japanese Journal of Clin. Oncol. 29 (11): 562–570. Template:ISSN. Retrieved 2007-02-26. Unknown parameter |coauthors= ignored (help)

External links

Template:Sex hormones

Template:WikiDoc Sources